Sznol M - Search Results

1

Erythropoietin production. A potential marker for interleukin-2/interferon-responsive tumors.

Janik JE, Sznol M, Urba WJ, Figlin R, Bukowski RM, Fyfe G, Pierce WC, Belldegrun A, Sharfman WH, Smith JW 2nd, et al. Janik JE, et al. Among authors: sznol m. Cancer. 1993 Nov 1;72(9):2656-9. doi: 10.1002/1097-0142(19931101)72:9<2656::aid-cncr2820720922>3.0.co;2-a. Cancer. 1993. PMID: 8402486

2

Intensive therapy with cisplatin, interleukin-2 and interferon-alpha-2a in patients with metastatic melanoma. A phase II Study.

Sznol M, Steis RG, Smith JW 2nd, Janik JE, Sharfman WH, Urba WJ, Fenton RG, Creekmore SP, Beveridge J, Longo DL. Sznol M, et al. Online J Curr Clin Trials. 1992 Jul 1;Doc No 9:[3841 words; 32 paragraphs]. Online J Curr Clin Trials. 1992. PMID: 1343617 Clinical Trial.

3

Adoptive cellular therapy.

Sznol M, Urba WJ. Sznol M, et al. Cancer Chemother Biol Response Modif. 1992;13:191-204. Cancer Chemother Biol Response Modif. 1992. PMID: 1389910 Review. No abstract available.

4

Anti-CD3 monoclonal antibody treatment of patients with CD3-negative tumors: a phase IA/B study.

Urba WJ, Ewel C, Kopp W, Smith JW 2nd, Steis RG, Ashwell JD, Creekmore SP, Rossio J, Sznol M, Sharfman W, et al. Urba WJ, et al. Among authors: sznol m. Cancer Res. 1992 May 1;52(9):2394-401. Cancer Res. 1992. PMID: 1533172 Clinical Trial.

5

Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.

Sznol M, Clark JW, Smith JW 2nd, Steis RG, Urba WJ, Rubinstein LV, VanderMolen LA, Janik J, Sharfman WH, Fenton RG, et al. Sznol M, et al. J Natl Cancer Inst. 1992 Jun 17;84(12):929-37. doi: 10.1093/jnci/84.12.929. J Natl Cancer Inst. 1992. PMID: 1629914

6

Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamine.

Urba WJ, Hartmann LC, Longo DL, Steis RG, Smith JW 2nd, Kedar I, Creekmore S, Sznol M, Conlon K, Kopp WC, et al. Urba WJ, et al. Among authors: sznol m. Cancer Res. 1990 May 15;50(10):2979-86. Cancer Res. 1990. PMID: 1692252

7

Prolonged, continuous treatment of hairy cell leukemia patients with recombinant interferon-alpha 2a.

Smith JW 2nd, Longo DL, Urba WJ, Clark JW, Watson T, Beveridge J, Conlon KC, Sznol M, Creekmore SP, Alvord WG, et al. Smith JW 2nd, et al. Among authors: sznol m. Blood. 1991 Oct 1;78(7):1664-71. Blood. 1991. PMID: 1912555 Free article.

8

Adoptive cellular therapy.

Sznol M, Urba WJ. Sznol M, et al. Cancer Chemother Biol Response Modif. 1991;12:213-30. Cancer Chemother Biol Response Modif. 1991. PMID: 1931444 Review. No abstract available.

9

A phase I study of high-dose interleukin-2 in combination with interferon-alpha 2b.

Sznol M, Mier JW, Sparano J, Gaynor ER, Weiss GR, Margolin KA, Bar MH, Hawkins MJ, Atkins MB, Dutcher JP, et al. Sznol M, et al. J Biol Response Mod. 1990 Dec;9(6):529-37. J Biol Response Mod. 1990. PMID: 2074439 Clinical Trial.

10

Adrenal insufficiency and interleukin-2 therapy.

VanderMolen LA, Smith JW 2nd, Longo DL, Steis RG, Kremers P, Sznol M. VanderMolen LA, et al. Among authors: sznol m. Ann Intern Med. 1989 Jul 15;111(2):185. doi: 10.7326/0003-4819-111-2-185_1. Ann Intern Med. 1989. PMID: 2787137 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

245 results

Search Page

Filters